TROP2-ADCs für fortgeschrittene HR-positive/HER2-negative und dreifach negative Krebserkrankungen: Neue Daten in die Praxis umsetzen

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
ADC anti-TROP2 nei tumori avanzati HR-positivi/HER2-negativi e triplo-negativi: dalla nuova evidenza alla pratica clinica

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Conjugados anticuerpo-fármaco (ADC) dirigidos a TROP2 en cáncer de mama avanzado RH positivo/ HER2 negativo y triple negativo: cómo trasladar los nuevos datos a la práctica

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Anticorps conjugués à des médicaments (ADC) TROP2 pour les cancers avancés HR-positifs/HER2-négatifs et triple-négatifs : Mettre les nouvelles données en pratique

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
TROP2 ADCs for Advanced HR-Positive/HER2-Negative and Triple-Negative Cancers: Translating New Data into Practice

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
EU Expert Think Tank: Global Perspectives and Clinical Resources to Optimize Antibody–Drug Conjugate Therapies in Metastatic HR-Positive/HER2-Negative or TNBC 

Content Format:

Video

Credit Type:

AMA | EBAC®

Credits:

0.25
Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer

Content Format:

Tool

Credit Type:

AMA | EBAC®

Credits:

0.25
PIK3CA/AKT1/PTEN Alterations Testing and Management of Patients With Locally Advanced or Metastatic Breast Cancer

Content Format:

Case Challenge

Credit Type:

AMA | EBAC®

Credits:

0.50
Expert Perspectives on Integrating Immuno-Oncology Therapeutics Into the Management of Metastatic Triple-Negative Breast Cancer

Content Format:

Text Module

Credit Type:

ACPE | AMA | ANCC

Credits:

1.00
Moving Immunotherapy Into Earlier Settings for Triple-Negative Breast Cancer

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--